L606, an inhaled treprostinil, for high lung blood pressure caused by interstitial lung disease
Tests inhaled L606 against placebo in adults with pulmonary hypertension from interstitial lung disease.
Plain-language title generated from the registry record
Registry title: A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD
Key facts
- Where
- Bath, London, Plymouth, and Sheffield, United KingdomSee the 5 sites
- Phase
- Phase 3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT07285655, who can take part
Where in United Kingdom
- Royal United Hospitals Bath NHS Foundation TrustBath, United KingdomTaking people
- Royal Bromptom HospitalLondon, United KingdomTaking people
- Royal Free London NHS Foundation Trust Hospital - Royal Free HospitalLondon, United KingdomTaking people
- University Hospitals Plymouth NHS Trust, Derriford HospitalPlymouth, United KingdomTaking people
- Sheffield Teaching Hospital NHS Foundation Trust - Royal Hallamshire HospitalSheffield, United KingdomTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Liquidia Technologies, Inc.
- Trial code
- NCT07285655
- Record updated
- 14 October 2026
- Original description
The purpose of this study is to find out if L606 is safe and if it helps people with high blood pressure in the lungs (pulmonary hypertension) caused by interstitial lung disease (PH-ILD, WHO Group 3). One of the main ways the study will check this is by seeing if people can walk further in six minutes (called the "six-minute walk test"). Another important (secondary) goal is to see how long it takes for PH-ILD to get worse while people are taking L606. One way the study will measure this is by looking at the distance people walk at different times in the study on different doses of L606. Throughout the study, doctors will also closely monitor for any side effects people have to make sure L606 is safe. People who decide to join this study will be randomly (like tossing a coin) placed into one of two groups: one group will get L606 and the other group will get a placebo, which will look like L606 but will not contain any active medicine. At the end of the initial blinded portion of the study, study participants may have the opportunity to enroll in an open-label extension portion of the study where all participants will receive L606.Read full original descriptionShow less
A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety and Efficacy of L606 (Treprostinil Liposome Inhalation Suspension) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (WHO Group 3)
The purpose of this study is to find out if L606 is safe and if it helps people with high blood pressure in the lungs (pulmonary hypertension) caused by interstitial lung disease (PH-ILD, WHO Group 3). One of the main ways the study will check this is by seeing if people can walk further in six minutes (called the "six-minute walk test"). Another important (secondary) goal is to see how long it takes for PH-ILD to get worse while people are taking L606. One way the study will measure this is by looking at the distance people walk at different times in the study on different doses of L606. Throughout the study, doctors will also closely monitor for any side effects people have to make sure L606 is safe. People who decide to join this study will be randomly (like tossing a coin) placed into one of two groups: one group will get L606 and the other group will get a placebo, which will look like L606 but will not contain any active medicine. At the end of the initial blinded portion of the study, study participants may have the opportunity to enroll in an open-label extension portion of the study where all participants will receive L606.
Inclusion: Participant is between 18 years to 80 years old; Has a confirmed diagnosis of ILD based on High Resolution Computed Tomography (HRCT) chest imaging; Evidence of PH as demonstrated from Right Heart Catheterization (RHC) with the following hemodynamic parameters:; Pulmonary vascular resistance (PVR) ≥ 320 dynes.sec/cm5 (i.e. 4 Woods Units (WU)), and; Mean Pulmonary Artery Pressure (mPAP) of ≥ 25 mmHg, and; - Pulmonary capillary wedge pressure (PCWP) or Left-Ventricular End Diastolic Pressure (LVEDP) of ≤ 15 mmHg; FEV1/FVC (ratio) > 0.70; 6-minute walk distance ≥ 150 meters.
Exclusion: Has evidence of clinically significant left-sided heart disease as defined by echocardiography; Participants with history of persistent/permanent or uncontrolled atrial fibrillation; Has experienced exacerbation of underlying lung disease or active respiratory infection requiring antibiotics; PH in the updated WHO Classification Groups 1, 2, 4, or 5; Participants with severe obstructive sleep apnea; Initiation of pulmonary rehabilitation; Note: Other protocol defined inclusion/exclusion criteria may apply.